Sign up
Pharma Capital

Arix Bioscience Plc portfolio company Iterum Therapeutics updates on its antibiotic drug

Arix Bioscience Plc (LON:ARIX) portoflio company Iterum Therapeutics Plc (NASDAQ:ITRM) CEO Corey Fishman tells Proactive's Christine Corrado the Dublin, Ireland based clinical stage biopharma company is in Phase 3 with its antibiotic drug Sulopenem.

Fishman says the company is developing the drug to treat multi-drug resistant infections, and stands out from its peers because Sulopenem is both an oral and IV drug, and he says there has not been a new oral product in this area in two decades.

Fishman says trials are expected to finish in the second half 2019.


View full ARIX profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.